Cyclarity's UDP-003 demonstrates the first clinical evidence that 7-ketocholesterol, a primary driver of atherosclerotic plaque formation, can be safely targeted and excreted from the human body. This represents a shift from managing cardiovascular disease progression to potential plaque reversal, with even modest reductions in plaque burden associated with significantly lower cardiovascular event risk.
Key Points
- UDP-003 safely binds and removes 7-ketocholesterol via urinary excretion
- First clinical evidence of oxidized cholesterol removal in humans
- 1% plaque reduction correlates with 25% lower cardiovascular event risk
Longevity Analysis
Cardiovascular disease remains the dominant mortality driver across populations, yet current therapeutics address symptoms and progression rather than the underlying pathology. Targeting 7-ketocholesterol directly addresses a root cause of plaque accumulation while avoiding systemic disruption—a mechanistic distinction that matters for both immediate cardiovascular protection and longer-term metabolic resilience. Since cardiovascular function underpins oxygen delivery, nutrient transport, and waste clearance to every tissue, treatments that restore arterial integrity and reduce inflammatory plaque burden preserve multiple downstream functions essential to healthy aging, including cognitive reserve, renal function, and metabolic stability.
Original published by LifeSpan.io, by Press release.